News

HT-ALZ Leads to Cognitive Improvements in Diseased Mice

Chronic treatment with HT-ALZ, Hoth Therapeutics‘ investigational oral therapy for Alzheimer’s disease, led to significant cognitive improvements in a mouse model of the neurodegenerative condition. The data were collected as part of Hoth’s ongoing sponsored research agreement with investigators at Washington University in St. Louis, Missouri, led by…

Grant Will Fund MedPharm Study of Cannabinoids’ Effects in Alzheimer’s

Cannabis researcher MedPharm has been granted funding to study the effect of phytocannabinoids — naturally occurring chemicals, called cannabinoids, from marijuana plants — on Alzheimer’s disease, with the ultimate aim of treatment development. The new funding comes from the Colorado State University Institute of Cannabis Research (ICR). It was…

1st Patient Dosed With Bryostatin as Developer Seeks Best Regimen

The first patient has been dosed in an open-label dose optimization trial of bryostatin, an investigational treatment for Alzheimer’s disease. According to the therapy’s developer, Synaptogenix — previously called Neurotrope — the dose-finding trial will prepare the company to move forward with bryostatin’s next phase of clinical…

Blood Biomarker Test Designated a Breakthrough Device

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Amyloid Plasma Panel, Roche’s blood-based biomarker test designed to enable earlier Alzheimer’s disease diagnoses. Breakthrough device designation is granted to medical devices that provide a more effective way of treating or diagnosing a life-threatening…

Multiple Doses Of AlzeCure’s ACD856 Safe, Well Tolerated

Repeated dosing of ACD856, an investigational therapy for Alzheimer’s disease, was generally safe and well tolerated in healthy adult volunteers, according to data from a now-completed Phase 1 trial. AlzeCure Pharma is developing ACD856 as its lead therapeutic candidate in the company’s NeuroRestore platform, which contains investigational therapies for…

FDA to Announce Decision on Lecanemab’s Approval in January 2023

The U.S. Food and Drug Administration (FDA) has agreed to review an application from Eisai seeking accelerated approval of lecanemab (BAN2401), an investigational amyloid-targeting antibody to treat early Alzheimer’s disease in people with confirmed amyloid plaques in the brain. Eisai finished the rolling application a few months ago.